Cancer Research SABCS  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 5057, June 15, 2009. Published Online First June 2, 2009;
doi: 10.1158/0008-5472.CAN-08-4287
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-4287v1
69/12/5057    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Dillon, R. L.
Right arrow Articles by Muller, W. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dillon, R. L.
Right arrow Articles by Muller, W. J.

Cell, Tumor, and Stem Cell Biology

Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression

Rachelle L. Dillon1,2, Richard Marcotte1, Bryan T. Hennessy4, James R. Woodgett5, Gordon B. Mills4 and William J. Muller1,2,3

1 Goodman Cancer Centre and Departments of 2 Biochemistry and 3 Medicine, McGill University, Montreal, Quebec, Canada; 4 Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and 5 Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

Requests for reprints: William J. Muller, McGill University, Room 509, Cancer Pavillion, 1160 Pine Avenue West, Montreal, Quebec, Canada H3G 0B1. Phone: 514-398-5847; Fax: 514-398-6769; E-mail: william.muller{at}mcgill.ca.

Key Words: Akt • ErbB2 • PyVmT • mammary tumorigenesis • metastasis

The phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway is often dysregulated in cancer. Our previous studies have shown that coexpression of activated Akt1 with activated ErbB2 or polyoma virus middle T antigen uncoupled from the PI3K pathway (PyVmT Y315/322F) accelerates mammary tumor development but cannot rescue the metastatic phenotype associated with these models. Here, we report the generation of transgenic mice expressing activated Akt2 in the mammary epithelium. Like the mouse mammary tumor virus-Akt1 strain, mammary-specific expression of Akt2 delayed mammary gland involution. However, in contrast to Akt1, coexpression of Akt2 with activated ErbB2 or PyVmT Y315/322F in the mammary glands of transgenic mice did not affect the latency of tumor development. Strikingly, Akt2 coexpresssion markedly increased the incidence of pulmonary metastases in both tumor models, demonstrating a unique role in tumor progression. Together, these observations argue that these highly conserved kinases have distinct biological and biochemical outputs that play opposing roles in mammary tumor induction and metastasis. [Cancer Res 2009;69(12):5057–64]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.